Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

Christian Schmidkonz,Simon Rauber,Armin Atzinger,Rahul Agarwal,Theresa Ida Götz,Alina Soare,Michael Cordes,Olaf Prante,Christina Bergmann,Arnd Kleyer,Philipp Ritt,Simone Maschauer,Peter Hennig,Johannes Toms,Markus Köhner,Bernhard Manger,John H Stone,Uwe Haberkorn,Tobias Baeuerle,Jörg H W Distler,Abbas Agaimy,Torsten Kuwert,Georg Schett,Andreas Ramming
DOI: https://doi.org/10.1136/annrheumdis-2020-217408
Abstract:Objectives: To date, there is no valuable tool to assess fibrotic disease activity in humans in vivo in a non-invasive way. This study aims to uncouple inflammatory from fibrotic disease activity in fibroinflammatory diseases such as IgG4-related disease. Methods: In this cross-sectional clinical study, 27 patients with inflammatory, fibrotic and overlapping manifestations of IgG4-related disease underwent positron emission tomography (PET) scanning with tracers specific for fibroblast activation protein (FAP; 68Ga-FAP inhibitor (FAPI)-04), 18F-fluorodeoxyglucose (FDG), MRI and histopathological assessment. In a longitudinal approach, 18F-FDG and 68Ga-FAPI-04 PET/CT data were evaluated before and after immunosuppressive treatment and correlated to clinical and MRI data. Results: Using combination of 68Ga-FAPI-04 and 18F-FDG-PET, we demonstrate that non-invasive functional tracking of IgG4-related disease evolution from inflammatory towards a fibrotic outcome becomes feasible. 18F-FDG-PET positive lesions showed dense lymphoplasmacytic infiltration of IgG4+ cells in histology, while 68Ga-FAPI-04 PET positive lesions showed abundant activated fibroblasts expressing FAP according to results from RNA-sequencing of activated fibroblasts. The responsiveness of fibrotic lesions to anti-inflammatory treatment was far less pronounced than that of inflammatory lesions. Conclusion: FAP-specific PET/CT permits the discrimination between inflammatory and fibrotic activity in IgG4-related disease. This finding may profoundly change the management of certain forms of immune-mediated disease, such as IgG4-related disease, as subtypes dominated by fibrosis may require different approaches to control disease progression, for example, specific antifibrotic agents rather than broad spectrum anti-inflammatory treatments such as glucocorticoids.
What problem does this paper attempt to address?